# Quantum-Si Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Quantum-Si Inc). ## Overview Quantum-Si Inc. is a U.S.-based life sciences instrumentation company focused on proteomics research through its Next-Gen Protein Sequencing platform. The company develops and commercializes the Platinum instrument family, consumables, software workflows, and related services for research laboratories and other scientific users. ## Products & services • Platinum instrument systems • Platinum Pro instrument • Library prep and barcoding kits • Sequencing kits and reagent consumables • Platinum Analysis Software and workflows • Training, maintenance, and technical support - **Instruments** (45%) — Benchtop proteomics sequencing instruments sold under the Platinum line, including Platinum Pro. - **Consumables** (40%) — Library prep kits, barcoding kits, sequencing kits, reagents, chips, and related disposables. - **Software and workflows** (5%) — Analysis software and computational workflows used to interpret proteomic data. - **Services** (10%) — Maintenance contracts, advanced training, and customer support services. - Platinum instrument systems - Platinum Pro instrument - Library prep and barcoding kits - Sequencing kits and reagent consumables - Platinum Analysis Software and workflows - Training, maintenance, and technical support ## Customers Quantum-Si sells to scientific users that need protein analysis tools for research and applied workflows. Its customer base includes academic researchers, biopharma companies, CDMOs, government labs, and industrial users that buy instruments, consumables, and support services to generate proteomic data. - **Academic research** (primary) — Universities and research institutes buy instruments and kits to study proteins and validate proteomics methods. - **Biopharma** (primary) — Drug discovery and development teams use the platform for protein characterization and translational research. - **CDMOs** (secondary) — Contract development and manufacturing organizations use the system for quality control testing and applied workflows. - **Government and industrial** (secondary) — Public-sector and industrial labs buy systems for research, assay development, and specialized protein analysis. - Academic research labs buying instruments for proteomics studies - Biopharma teams using the platform for drug discovery and development - CDMOs and translational labs using it for quality control and workflows - Government and industrial labs needing protein analysis capabilities - Customers buying consumables and software after instrument placement ## Geography Quantum-Si is headquartered in the United States and sells directly there, while Europe is served through a mix of direct and distributor channels. The company also uses distributors in selected markets across Europe, the Middle East, Africa, Asia Pacific, and South America, which broadens reach but adds reliance on partners. - United States is the core direct-sales market - Europe uses a combined direct and distributor model - Distributor partners extend reach into EMEA, APAC, and South America - Western Europe is a stated commercial focus - Geographic partner network supports international adoption ## Strategy Quantum-Si is focused on commercializing its proteomics platform by expanding sales coverage, generating scientific evidence, and adding product generations. It is also building partnerships and technical support capabilities to improve adoption across research and applied markets. - **Commercialize the Platinum platform** (short-term) — Instrument placement and consumable pull-through are central to building a recurring proteomics business. - **Expand product roadmap** (medium-term) — New instruments, kits, and software increase application breadth and customer retention. - **Build scientific validation** (medium-term) — Proteomics adoption depends on published evidence and KOL support for the platform's utility. - **Protect intellectual property** (long-term) — Patent coverage helps defend the platform and reduce fast-follower risk. - Expand direct sales and support in the U.S. and Western Europe - Use distributors to extend international market coverage - Generate scientific evidence through KOLs and collaborations - Launch new instruments and workflows to broaden use cases - Protect intellectual property around core proteomics technology ## Risks Quantum-Si faces the typical risks of an early-stage life sciences tools company: adoption uncertainty, limited operating history, and dependence on continued funding. Its business also depends on successful commercialization, partner execution, and maintaining intellectual property around a technically differentiated platform. - **Commercialization risk** [high] — Revenue depends on convincing researchers and labs to adopt a new proteomics platform. - **Funding and liquidity risk** [high] — The company has historically negative cash flow and may need debt or equity financing to support operations. - **Limited operating history** [medium] — The company has not yet established a long track record of scaled commercialization. - **Intellectual property risk** [high] — The platform relies on patents and licensed IP; loss of protection could weaken differentiation. - **Partner/channel execution risk** [medium] — International growth depends partly on distributors and third-party sales partners. - **AI and machine learning compliance risk** [low] — Use of AI/ML in internal functions may create regulatory and legal exposure. - Limited operating history makes future demand hard to predict - Commercial adoption may be slower than expected - Sales and distribution execution is critical to market acceptance - Ongoing cash needs may require external financing - Patent protection is important to defend the platform - AI/ML use creates legal and compliance exposure ## Accounting Revenue comes from instrument sales, consumables, freight, and service contracts, so timing can vary with shipment, installation, and maintenance coverage. Investors should also watch estimates tied to inventory write-offs, warranty costs, royalty obligations, and the valuation of marketable securities and other assets in a company still building scale. - **Revenue recognition by product and service type** — Reported revenue mix and timing - **Inventory valuation and write-offs** — Cost of revenue and gross profit - **Warranty and service obligations** — Operating expenses and cost of revenue - **Royalty and licensed IP payments** — Cost structure and liquidity - **Fair value estimates for investments** — Balance sheet and other income/expense - Instrument revenue is recognized on shipment or delivery terms - Consumables drive recurring revenue and can create quarterly volatility - Service contracts and software access affect timing of service revenue - Inventory write-offs and warranty reserves can move gross profit - Royalty and licensed IP payments affect cost of revenue - Fair value of marketable securities affects balance sheet estimates --- *Last updated: 2026-04-29T04:50:44.715267+00:00*